{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:24:20Z","timestamp":1789133060591,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010668","name":"Population and Family Planning Commission of Shandong Province","doi-asserted-by":"crossref","award":["2018GSF118227"],"award-info":[{"award-number":["2018GSF118227"]}],"id":[{"id":"10.13039\/501100010668","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The goal of this study was to investigate the clinical and pathological features and prognosis of idiopathic membranous nephropathy (IMN) with focal segmental lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In our hospital, 305 patients with nephrotic syndrome confirmed as IMN by renal biopsy were divided into a non-focal segmental lesion group (FSGS- group) and a focal segmental glomerulosclerosis (FSGS) group (FSGS+ group) and retrospectively analyzed. In all, 180 patients were followed for periods ranging from 6 months to 2 years. The general clinicopathological data of both groups were compared, and the effects of different treatment schemes on the prognosis of both groups were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The FSGS+ group had a longer disease course, higher blood pressure levels, and higher serum creatinine and \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -microglobulin levels than did the FSGS- group (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Pathologically, the FSGS+ group had increased glomerular sclerosis, glomerular mesangial hyperplasia, and acute and chronic tubular lesion rates (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). The remission rate was lower in the FSGS+ group than in the FSGS- group (64.7% vs 82.2%) and, among patients in the FSGS+ group, was lower in patients treated with calmodulin inhibitors than in those treated with cyclophosphamide (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Survival analysis showed that the FSGS+ group had a poor prognosis (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20094.377,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.036), and risk factor analysis suggested that age at renal biopsy (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006), 24-h urinary protein quantity (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01), chronic tubulointerstitial lesions (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.055), and FSGS lesions (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.062) were risk factors for worsening renal condition; furthermore, 24-h urinary protein quantity was an independent risk factor for worsening renal condition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Membranous nephropathy with FSGS is a risk factor, but not an independent risk factor, for IMN. Patients with membranous nephropathy with FSGS often present hypertension and tubule injury. The nonselective drug cyclophosphamide is preferred, and calcineurin inhibitors should be used with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-019-1641-2","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T11:02:37Z","timestamp":1576494157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis"],"prefix":"10.1186","volume":"20","author":[{"given":"Jiatong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"issue":"9981","key":"1641_CR1","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","volume":"385","author":"P Ronco","year":"2015","unstructured":"Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015;385(9981):1983\u201392.","journal-title":"Lancet"},{"issue":"1","key":"1641_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molimm.2015.07.003","volume":"68","author":"P Ronco","year":"2015","unstructured":"Ronco P, Debiec H. Membranous nephropathy: a fairy tale for immunopathologists, nephrologists and patients. Mol Immunol. 2015;68(1):57\u201362.","journal-title":"Mol Immunol"},{"issue":"6","key":"1641_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","volume":"12","author":"WG Couser","year":"2017","unstructured":"Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983\u201397.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1641_CR4","doi-asserted-by":"publisher","first-page":"249740","DOI":"10.1155\/2015\/249740","volume":"2015","author":"B Obrisca","year":"2015","unstructured":"Obrisca B, Ismail G, Jurubita R, Baston C, Andronesi A, Mircescu G. Antiphospholipase A2 receptor autoantibodies: a step forward in the management of primary membranous nephropathy. Biomed Res Int. 2015;2015:249740.","journal-title":"Biomed Res Int"},{"issue":"4","key":"1641_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","volume":"21","author":"N Polanco","year":"2010","unstructured":"Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697\u2013704.","journal-title":"J Am Soc Nephrol"},{"key":"1641_CR6","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/j.1523-1755.2004.00518.x","volume":"65","author":"H SHIIKI","year":"2004","unstructured":"SHIIKI H, SAITO T, NISHITANI Y, MITARAI T, YORIOKA N, YOSHIMURA A, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400\u20137.","journal-title":"Kidney Int"},{"issue":"1","key":"1641_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/ajkd.2003.50015","volume":"41","author":"A Dumoulin","year":"2003","unstructured":"Dumoulin A, Hill GS, Montseny JJ, Meyrier A. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis. 2003;41(1):38\u201348.","journal-title":"Am J Kidney Dis"},{"key":"1641_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/ki.1992.59","volume":"41","author":"S Wakai","year":"1992","unstructured":"Wakai S. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int. 1992;41:428\u201334.","journal-title":"Kidney Int"},{"issue":"4","key":"1641_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","volume":"93","author":"AE van de Logt","year":"2018","unstructured":"van de Logt AE, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93(4):1016\u20137.","journal-title":"Kidney Int"},{"issue":"6","key":"1641_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.5414\/CN107681","volume":"79","author":"K Zuo","year":"2013","unstructured":"Zuo K, Wu Y, Li SJ, Xu F, Zeng CH, Liu ZH. Long-term outcome and prognostic factors of idiopathic membranous nephropathy in the Chinese population. Clin Nephrol. 2013;79(6):445\u201353.","journal-title":"Clin Nephrol"},{"issue":"3","key":"1641_CR11","first-page":"307","volume":"27","author":"Y Chen","year":"2014","unstructured":"Chen Y, Tang L, Feng Z, Cao X, Sun X, Liu M, et al. Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function. Ital Soc Nephrol. 2014;27(3):307\u201316.","journal-title":"Ital Soc Nephrol"},{"issue":"2","key":"1641_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/nep.12952","volume":"23","author":"C Bazzi","year":"2018","unstructured":"Bazzi C, Usui T, Rizza V, Casellato D, Gallieni M, Nangaku M. Urinary N-acetyl-beta-glucosaminidase and estimated glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy. Nephrology (Carlton). 2018;23(2):175\u201382.","journal-title":"Nephrology (Carlton)"},{"issue":"2","key":"1641_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/ndt\/gfp521","volume":"25","author":"R Gupta","year":"2010","unstructured":"Gupta R, Sharma A, Mahanta PJ, Jacob TG, Agarwal SK, Roy TS, et al. Focal segmental glomerulosclerosis in idiopathic membranous glomerulonephritis: a clinico-pathological and stereological study. Nephrol Dial Transplant. 2010;25(2):444\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1641_CR14","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1093\/ndt\/gfm188","volume":"22","author":"SF Heeringa","year":"2007","unstructured":"Heeringa SF, Branten AJ, Deegens JK, Steenbergen E, Wetzels JF. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy. Nephrol Dial Transplant. 2007;22(8):2201\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"21","key":"1641_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003786","volume":"95","author":"QH Gu","year":"2016","unstructured":"Gu QH, Cui Z, Huang J, Zhang YM, Qu Z, Wang F, et al. Patients with combined membranous nephropathy and focal segmental Glomerulosclerosis have comparable clinical and autoantibody profiles with primary membranous nephropathy: a retrospective observational study. Medicine (Baltimore). 2016;95(21):e3786.","journal-title":"Medicine (Baltimore)"},{"key":"1641_CR16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"A Troyanov Se","year":"2014","unstructured":"Troyanov Se A, Wall CA, Miller JW, Scholey JC, Cattran D. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2014;66:1199\u2013205.","journal-title":"Kidney Int"},{"issue":"6","key":"1641_CR17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/S0272-6386(99)70138-1","volume":"33","author":"BJ Laluck","year":"1999","unstructured":"Laluck BJ, Cattran DC. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis. 1999;33(6):1026\u201332.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1641_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga M, Barrio V, Juarez GF, Luno J. Grupo Espanol de Estudio de la Nefropatia M. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924\u201330.","journal-title":"Kidney Int"},{"issue":"4","key":"1641_CR19","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.ajpath.2011.06.033","volume":"179","author":"T Nijenhuis","year":"2011","unstructured":"Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011;179(4):1719\u201332.","journal-title":"Am J Pathol"},{"issue":"6","key":"1641_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1681\/ASN.2007121292","volume":"19","author":"MP Winn","year":"2008","unstructured":"Winn MP. 2007 young investigator award: TRP'ing into a new era for glomerular disease. J Am Soc Nephrol. 2008;19(6):1071\u20135.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1641_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11596-015-1480-8","volume":"35","author":"ZQ Li","year":"2015","unstructured":"Li ZQ, Hu ML, Zhang C, Wang YM. Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: a meta-analysis of Chinese adults. J Huazhong Univ Sci Technolog Med Sci. 2015;35(5):623\u20138.","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"25","key":"1641_CR22","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1056\/NEJM199206183262502","volume":"329","author":"C Feutren","year":"1992","unstructured":"Feutren C. J. Mihatsch M. risk factors for cyclosporine induced nephropathy in patients with autoimmune diseases. N Engl J Med. 1992;329(25):1654\u201360.","journal-title":"N Engl J Med"},{"issue":"11","key":"1641_CR23","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1681\/ASN.2010040378","volume":"21","author":"J Peti-Peterdi","year":"2010","unstructured":"Peti-Peterdi J, Sipos A. A high-powered view of the filtration barrier. J Am Soc Nephrol. 2010;21(11):1835\u201341.","journal-title":"J Am Soc Nephrol"},{"issue":"7\u20138","key":"1641_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00424-017-2023-x","volume":"469","author":"M Nagata","year":"2017","unstructured":"Nagata M, Kobayashi N, Hara S. Focal segmental glomerulosclerosis; why does it occur segmentally? Pflugers Arch. 2017;469(7\u20138):983\u20138.","journal-title":"Pflugers Arch"},{"issue":"9","key":"1641_CR25","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1517\/14656566.6.9.1539","volume":"6","author":"A Meyrier","year":"2005","unstructured":"Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert Opin Pharmacother. 2005;6(9):1539\u201349.","journal-title":"Expert Opin Pharmacother"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1641-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T19:19:41Z","timestamp":1607973581000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1641-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1641"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1641-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.12239\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12239\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12239\/v3","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"6 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data collection of related cases has been approved by the Ethics Committee of the Affiliated Provincial Hospital of Shandong University (LCYJ: No. 2019\u2013105). Oral and written informed consent to participation is obtained from all study participants by study personnel prior to any study related procedure. All participants receive both written and oral information about the study before giving consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"467"}}